Scientists at a medical center in Taiwan evaluated the mycology database of the National Taiwan University Hospital and patients diagnosed
with candidaemia due to C. parapsilosis sensu lato species from 2000 to 2012.
A total of 323 adult patients with candidaemia caused by C. parapsilosis sensu lato species were evaluated, including 256 (79.3%) patients with
C. parapsilosis sensu stricto, 34 (10.5%) with C. orthopsilosis, and 33 (10.2%) with C. metapsilosis. There were 222 men and 101 women and
the median age was 60 years (range, 18 to 103 years). Among them, 178 (55%) had an underlying diagnosis of cancer. The overall 30-day mortality rate was 25% (n= 80). Multivariate analysis revealed that shock (P< 0. 001 ), anti-fungal therapy (P= 0. 002), central catheter removal (P= 0. 02), and abdominal surgery (P= 0. 043) were independent prognostic factors of patients
with candidaemia due to C. parapsilosis sensu lato species. There were no significant differences in 30-day mortality rate among patients with candidaemia caused by the three different species (P= 0. 770). All isolates of C. metapsilosis, C.
orthopsilosis, and C. parapsilosis sensu stricto were susceptible to voriconazole. Wild type isolates were susceptible to itraconazole,
posaconazole and amphotericin B.
Conclusions: There were no significant differences in 30day mortality among patients with candidaemia caused by C. parapsilosis sensu stricto,
C. metapsilosis or C. orthopsilosis. The currently used anti-fungal agents exhibited good in-vitro activities against C. parapsilosis sensu lato species
isolates.
Copyright @ 2015 Tianjin Era Biology Technology Co., Ltd.All Rights Reserved.